New Leadership take charge at Dr. Datsons Labs Ltd, New Management to drive export market

Mr. Mahesh Vaidya takes charge as the Vice Chairman and Managing Director & Mr. Sameer Talim as the new Chief Executive officer.
 
 
Mr.Samir Talim, CEO, Dr.Datsons Labs Ltd
Mr.Samir Talim, CEO, Dr.Datsons Labs Ltd
MUMBAI, India - Feb. 14, 2015 - PRLog -- New Leadership take charge at Dr. Datsons Labs Ltd, New Management to drive export market of Dr. Datsons’s branded generics. Mr. Mahesh Vaidya takes charge as the Vice Chairman and Managing Director & Mr. Sameer Talim as the  new Chief Executive officer. Saturday, 14th February 2015, Mumbai, Maharashtra. In a major development to the top leadership change in the listed Pharma Company Dr. Datsons Labs Ltd, the announcement has come from the Meeting of the Board of Directors of the Company held on February 14, 2015. The salient features of the unaudited financial results seem to indicate a positive vibe as the sales is up 15% & net profit up from 1.97lakhs to 1.99 lakhs.

Dr.Datsons Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2015, inter alia, has decided to appoint Mr. Mahesh Vaidya, as the Vice Chairman and Managing Director of the Company w.e.f. February 14, 2015. Dr. Kannan Vishwanath, as the Vice Chairman and Managing Director of the Company has stepped down from the post  w.e.f. February 14, 2015. Dr.Datsons Labs Ltd had earlier appointed Mr. Sameer Talim as the  Chief Executive officer of the Company, with effect from February 09, 2015.

Sources to Pharmaleaders reveal that the appointment of Mr. Samir Talim as the CEO of Dr. Datsons Labs Ltd will be primarily to drive the company’s presence in the major markets & to aggressively build on the export orders, work on existing clients & as well as to generate new business give push to the Generic barands of Dr Datsons in Middle East, South East asia & South America. The new CEO  will also push Registrations of our formulations & enter new markets using his expertise in these markets. Mr. Samir has wide exposures in the export markets based on his successful stints in the previous assignments will help Dr. Datsons Labs penetration into the key market. India ofcourse will remain as the Key market as the company still has big companies in Contract Manufacturing.  Mr. Mahesh Vaidya  as the new Vice-Chairman & Managing Director will aggressively look into equity raising for the company. Mr. Mahesh Vaidya is entrusted with the responsibilities to meet  with the  potential investors for stake sale or fresh infusions of funds into  the company which is quite vital for the growth momentum of Dr. Datsons Labs. Ltd. There are key unfinished agenda as certain vital deals are yet to be given a finishing end including the current proposals to give new & fresh perspectives.In an exclusive interview to Pharmaleaders , the new Vice-Chairman & MD, Mr Mahesh Vaidya expressed hope that the coming I year is going to be very crucial to the company’s both organic & inorganic growth as many deals, JV’s & partnership are pending for the final clearances, Dr. Datsons Labs will be closely looking at the operational efficiency of the Mahad Facility for Making APIs for Captive Use of APIs for their formulations. There are interesting & exciting times ahead of us, we all are committed to bring the company to its new height. Commenting on the state of india’s booming Pharma market, Mr Vaidya stated that India has become a prime destination for manufacture of branded, generic and branded generic medicines with a strong export element. It is estimated that around 40 per cent of the generic drugs in the US come from India and with Obamacare being introduced this figure is set to rise further. Overall market seems positive & our new CEO Mr. Sameer Talim will drive the domestic as well as the exports market, soon we will announce a breakthrough export deal that we have received from Nigeria & Yemen.Mr. Sameer Talim stated that “Indian pharmaceutical companies have capitalised on export opportunities in regulated and semi-regulated markets and pharma exports from India grew at a CAGR in excess of 20% from 2006 to 2012. Currently, India is the third-largest exporter of Active Pharmaceutical Ingredients (APIs). Indian pharma exports are expected to bring in an estimated $40 billion by the First Quarter of 2015. With Indian products competing with their global counterparts in terms of quality, India has been able to establish a global footprint. Indian companies operating in the west have been able to do so successfully & Dr. Datsons Lab is fully equipped to meet the challenges both regulatory & operationally to cater to the world market. We are expecting a 30 % jump in exports in the second quarter which will largely be driven by the generic push”.

Contact
Network 7 Media Group
***@network7mediagroup.com
End
Email:***@network7mediagroup.com Email Verified
Tags:Mahesh Vaidya, Sameer Talim, Dr Datsons Labs
Industry:Biotech, Health
Location:Mumbai - Maharashtra - India
Subject:Features
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Network7mediagroup News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share